AIRLINK 72.59 Increased By ▲ 3.39 (4.9%)
BOP 4.99 Increased By ▲ 0.09 (1.84%)
CNERGY 4.29 Increased By ▲ 0.03 (0.7%)
DFML 31.71 Increased By ▲ 0.46 (1.47%)
DGKC 80.90 Increased By ▲ 3.65 (4.72%)
FCCL 21.42 Increased By ▲ 1.42 (7.1%)
FFBL 35.19 Increased By ▲ 0.19 (0.54%)
FFL 9.33 Increased By ▲ 0.21 (2.3%)
GGL 9.82 Increased By ▲ 0.02 (0.2%)
HBL 112.40 Decreased By ▼ -0.36 (-0.32%)
HUBC 136.50 Increased By ▲ 3.46 (2.6%)
HUMNL 7.14 Increased By ▲ 0.19 (2.73%)
KEL 4.35 Increased By ▲ 0.12 (2.84%)
KOSM 4.35 Increased By ▲ 0.10 (2.35%)
MLCF 37.67 Increased By ▲ 1.07 (2.92%)
OGDC 137.75 Increased By ▲ 4.88 (3.67%)
PAEL 23.41 Increased By ▲ 0.77 (3.4%)
PIAA 24.55 Increased By ▲ 0.35 (1.45%)
PIBTL 6.63 Increased By ▲ 0.17 (2.63%)
PPL 125.05 Increased By ▲ 8.75 (7.52%)
PRL 26.99 Increased By ▲ 1.09 (4.21%)
PTC 13.32 Increased By ▲ 0.24 (1.83%)
SEARL 52.70 Increased By ▲ 0.70 (1.35%)
SNGP 70.80 Increased By ▲ 3.20 (4.73%)
SSGC 10.54 No Change ▼ 0.00 (0%)
TELE 8.33 Increased By ▲ 0.05 (0.6%)
TPLP 10.95 Increased By ▲ 0.15 (1.39%)
TRG 60.60 Increased By ▲ 1.31 (2.21%)
UNITY 25.10 Decreased By ▼ -0.03 (-0.12%)
WTL 1.28 Increased By ▲ 0.01 (0.79%)
BR100 7,566 Increased By 157.7 (2.13%)
BR30 24,786 Increased By 749.4 (3.12%)
KSE100 71,902 Increased By 1235.2 (1.75%)
KSE30 23,595 Increased By 371 (1.6%)

ISLAMABAD: Minister for National Health Services, Regulations and Coordination Abdul Qadir Patel has said that pharmaceutical company GSK is still manufacturing and supplying Panadol products in Pakistan.

Talking to media, the minister denied reports regarding the suspension of manufacturing of Panadol products by the Glaxo Smith Kline Consumer Healthcare Pakistan Ltd (GSK) in Pakistan.

“We want to facilitate the pharmaceutical industry in the country and the pricing issue of medicine concerned is being discussed with the relevant quarters.”

He said that a meeting was held in that regard to discuss various aspects. “The incumbent government will take a decision keeping in view the difficulties of the general public.”

Meanwhile, pharmaceutical company Glaxo Smith Kline Consumer Healthcare Pakistan Ltd also said that GSK had continued to manufacture and supply Panadol products and made it clear that the company had not stopped its production of Panadol products as reported in some sections of the media.

“We have been an integral part of the health sector for many years and contributing to the economic growth and stability of Pakistan with our products and local manufacturing footprint,” the GSK representative said in a company’s press release.

He expressed the hope that the ministry would address their genuine issues including rationalized pricing to ensure delivering better healthcare services to Pakistanis.

An official of the Pakistan Pharmaceutical Manufacturers Association (PPMA) said that despite challenges, the pharma company had continued the production of Panadol products for patients.

Comments

Comments are closed.